Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02170844
Recruitment Status : Completed
First Posted : June 23, 2014
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single rising doses from 50 mg to 350 mg in healthy male subjects of Japanese and Caucasian origin. This was the first administration of this substance to subjects of Japanese origin.

Condition or disease Intervention/treatment Phase
Healthy Drug: BIBR 1048 MS Drug: Placebo of BIBR 1048 MS Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of 50, 150 and 350 mg BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin. Double-blind at Each Dose Level, Placebo-controlled, Randomised Study
Study Start Date : June 2004
Actual Primary Completion Date : August 2004

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIBR 1048 MS (Japanese)
Japanese subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
Drug: BIBR 1048 MS
Placebo Comparator: BIBR 1048 MS Placebo (Japanese)
Japanese subjects will receive placebo of BIBR 1048 MS
Drug: Placebo of BIBR 1048 MS
Experimental: BIBR 1048 MS (Caucasian)
Caucasian subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
Drug: BIBR 1048 MS
Placebo Comparator: BIBR 1048 MS Placebo (Caucasian)
Japanese subjects will receive placebo of BIBR 1048 MS
Drug: Placebo of BIBR 1048 MS



Primary Outcome Measures :
  1. Change from baseline in blood pressure (BP) [ Time Frame: At screening (day -14 to -3), at day -1, pre-dose, 2, 8, 24, 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  2. Change from baseline in pulse rate (PR) [ Time Frame: At screening (day -14 to -3), at day -1, pre-dose, 2, 8, 24, 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  3. Change from baseline in respiratory rate [ Time Frame: At screening (day -14 to -3), at day -1, pre-dose, 2, 8, 24, 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  4. Change from baseline in tympanic body temperature [ Time Frame: At screening (day -14 to -3), at day -1, pre-dose, 2, 8, 24, 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  5. Change from baseline in 12-Lead electrocardiogram (ECG) [ Time Frame: At screening (day -14 to -3), at day -1, pre-dose, 2, 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  6. Change from baseline in haematology [ Time Frame: At screening (day -14 to -3), at day -1 (pre-dose), 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  7. Change from baseline in blood chemistry [ Time Frame: At screening (day -14 to -3), at day -1 (pre-dose), 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  8. Change from baseline in urinalysis [ Time Frame: At screening (day -14 to -3), at day -1 (pre-dose), 4, 8, 12, 24, 36, 48 h after administration and on visit 5 (day 10 to day 14 after administration) ]
  9. Occurence of adverse events [ Time Frame: Up to visit 5 (day 10 - 14) ]

Secondary Outcome Measures :
  1. Cmax (maximum concentration of the analyte in plasma) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  2. tmax (time from dosing to maximum concentration) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  3. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  4. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable point) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  5. λz (terminal rate constant in plasma) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  6. t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  7. MRTpo (mean residence time of the analyte in the body after po administration) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  8. CL/F (apparent clearance of the analyte in the plasma after extravascular administration) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  9. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
    (Pharmacokinetic parameters)

  10. Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2) [ Time Frame: pre-dose and 0-4, 4-8, 8-12, 12-24, 24-36 and 36-48 h after administration ]
  11. fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2) [ Time Frame: pre-dose and 0-4, 4-8, 8-12, 12-24, 24-36 and 36-48 h after administration ]
  12. CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) [ Time Frame: pre-dose and 0-4, 4-8, 8-12, 12-24, 24-36 and 36-48 h after administration ]
  13. Change from baseline for activated Partial Thromboplastin Time (aPTT) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  14. Change from baseline for Ecarin clotting time (ECT) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
    (Pharmacodynamic parameters)

  15. Change from baseline for thrombin time (TT) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]
  16. Change from baseline for international normalised ratio (INR) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (BP, PR, Respiratory Rate and tympanic body temperature), 12- lead ECG, clinical laboratory tests

    • 1.1. No finding deviating from normal and of clinical relevance
    • 1.2. No evidence of a clinically relevant concomitant disease
  2. Age ≥20 and Age ≤45 years
  3. BMI ≥18 and BMI ≤25 kg/m2 (Body Mass Index)
  4. Japanese subjects were from a well-defined Japanese population, both parents of Japanese origin and the subjects have Japanese passport and had lived ≤ 8 years outside Japan.
  5. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation.

Exclusion Criteria:

  1. Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women, or an unwillingness if the male subject to use an adequate form of contraception as well as having their female partner(s) use another form of contraception (if the woman could become pregnant) from the time of the first dose administration until after follow up
  3. Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
  4. History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts.
  5. Chronic or relevant acute infections
  6. History of - allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator

    • any bleeding disorder including prolonged or habitual bleeding
    • other hematologic disease
    • cerebral bleeding (e.g. after a car accident)
    • concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
  7. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
  8. Use of Acetylsalicylic-Acid (ASA)-containing over-the-counter medications, clopidogrel or ticlopidine or dipyridamole, chronic administration of Non Steroidal Antiinflammatory Drugs (NSAIDs) (COX-2 inhibitors excluded), coumadin like anticoagulants, chronic use of corticosteroids, heparin and fibrinolytic agents within 14 days prior to administration or during the trial.
  9. Use of all other medication including over the counter (medicinal cream, vitamin, eye drop etc.) within 7 days prior to administration or during the trial.
  10. Participation in another trial with an investigational drug within three months prior to administration or during the trial
  11. Smoker (> 10 cigarettes/day or > 3 cigars/day or > 3 pipes/day)
  12. Inability to refrain from smoking on trial days
  13. Alcohol abuse (more than 21unit/week)
  14. History of drug abuse
  15. Blood donation (more than 100 mL within three months prior to screening administration and any blood donation from screening to follow-up)
  16. Excessive physical activities (within one week prior to administration or during the trial and until follow-up)
  17. Any laboratory value outside the reference range that is of clinical relevance
  18. Inability to comply with dietary regimen of study centre
  19. Known hypersensitivity to the drug or its excipients

    Exclusion criteria specific for this study:

  20. History of any familial bleeding disorder
  21. Thrombocytes < 150000/micro L

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02170844     History of Changes
Other Study ID Numbers: 1160.28
First Posted: June 23, 2014    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Dabigatran
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants